Efficacy of respiratory quinolones for the treatment of community acquired pneumonia: a randomized controlled trial of moxifloxacin versus garenoxacin.

Trial Profile

Efficacy of respiratory quinolones for the treatment of community acquired pneumonia: a randomized controlled trial of moxifloxacin versus garenoxacin.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2012

At a glance

  • Drugs Garenoxacin (Primary) ; Moxifloxacin (Primary)
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Nov 2012 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 23 Jul 2011 Actual initiation date (May 2011) as reported by University Hospital Medical Information Network - Japan.
    • 23 Jul 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top